Significant survival benefit and favorable safety profile with pembrolizumab vs chemotherapy maintained in extended follow-up.
ORR increased from previous report with longer follow-up and 18-gene GEP score significantly associated with response.
In patients with advanced urothelial carcinoma, epacadostat plus pembrolizumab well tolerated, with ORR of 35% (DCR: 53%) in this patient cohort.
Adjuvant pazopanib at 600 mg after nephrectomy did not prolong DFS compared with placebo in patients with locally advanced RCC.
Epacadostat plus pembrolizumab safe, active in patients with advanced RCC with 47% ORR in patients who received ≤ 1 previous line of therapy.